On this page

Study design

A randomized, double-blind pilot assigned 54 people with cognitive impairment described as mild-to-moderate MCI to GeNeurofil or placebo for six months while they continued usual medications. The supplement was given as 0.7 mL three times daily; researchers assessed MMSE, Clinical Dementia Rating, mood and plasma NfL and phosphorylated tau.

Findings

The authors reported six-month differences favoring GeNeurofil on CDR and MMSE, and lower plasma NfL and p-tau than placebo. Zung depression scores changed over time, but showed no treatment or treatment-by-time effect.

Limits and disclosures

The sample was small, the study was retrospectively registered, and the trial was industry funded. Results are preliminary and do not establish clinical efficacy. The authors explicitly say larger trials are needed to confirm the findings.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news